Gary J. Moet

2.9k total citations
24 papers, 2.3k citations indexed

About

Gary J. Moet is a scholar working on Infectious Diseases, Epidemiology and Clinical Biochemistry. According to data from OpenAlex, Gary J. Moet has authored 24 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Infectious Diseases, 12 papers in Epidemiology and 9 papers in Clinical Biochemistry. Recurrent topics in Gary J. Moet's work include Antimicrobial Resistance in Staphylococcus (11 papers), Antifungal resistance and susceptibility (10 papers) and Bacterial Identification and Susceptibility Testing (9 papers). Gary J. Moet is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (11 papers), Antifungal resistance and susceptibility (10 papers) and Bacterial Identification and Susceptibility Testing (9 papers). Gary J. Moet collaborates with scholars based in United States, Brazil and Japan. Gary J. Moet's co-authors include Ronald N. Jones, Douglas J. Biedenbach, S. A. Messer, Mariana Castanheira, Michael A. Pfaller, Thomas R. Fritsche, Matthew G. Stilwell, Lalitagauri M. Deshpande, Hélio S. Sader and Jeffrey T. Kirby and has published in prestigious journals such as Journal of Clinical Microbiology, Antimicrobial Agents and Chemotherapy and Clinical Microbiology and Infection.

In The Last Decade

Gary J. Moet

24 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary J. Moet United States 19 1.7k 1.1k 612 314 305 24 2.3k
Barbara Fiori Italy 25 1.2k 0.7× 1.2k 1.1× 733 1.2× 796 2.5× 205 0.7× 64 2.6k
Leonard B. Johnson United States 27 2.0k 1.2× 1.2k 1.1× 887 1.4× 197 0.6× 484 1.6× 90 2.7k
S. J. van Hal Australia 18 1.7k 1.0× 655 0.6× 1.0k 1.7× 221 0.7× 365 1.2× 20 2.4k
D. Milatović Germany 23 1.1k 0.7× 722 0.7× 588 1.0× 721 2.3× 264 0.9× 59 2.2k
Barbara Zimmer United States 21 784 0.5× 952 0.9× 433 0.7× 322 1.0× 144 0.5× 41 2.0k
Eduardo Rodríguez-Noriega Mexico 29 991 0.6× 767 0.7× 417 0.7× 753 2.4× 167 0.5× 110 2.3k
Paul Lephart United States 28 947 0.6× 937 0.9× 551 0.9× 941 3.0× 247 0.8× 75 2.4k
Stacy L. Coffman United States 13 1.1k 0.7× 1.3k 1.2× 228 0.4× 281 0.9× 141 0.5× 18 1.9k
Josefina Ayats Spain 31 2.2k 1.3× 2.1k 1.9× 519 0.8× 1.0k 3.2× 354 1.2× 54 3.9k
V. Krčméry Slovakia 25 1.8k 1.1× 1.6k 1.4× 266 0.4× 165 0.5× 234 0.8× 124 2.7k

Countries citing papers authored by Gary J. Moet

Since Specialization
Citations

This map shows the geographic impact of Gary J. Moet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary J. Moet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary J. Moet more than expected).

Fields of papers citing papers by Gary J. Moet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary J. Moet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary J. Moet. The network helps show where Gary J. Moet may publish in the future.

Co-authorship network of co-authors of Gary J. Moet

This figure shows the co-authorship network connecting the top 25 collaborators of Gary J. Moet. A scholar is included among the top collaborators of Gary J. Moet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary J. Moet. Gary J. Moet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pfaller, Michael A., S. A. Messer, Gary J. Moet, Ronald N. Jones, & Mariana Castanheira. (2011). Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009). International Journal of Antimicrobial Agents. 38(1). 65–69. 213 indexed citations
2.
Sader, Hélio S., Gary J. Moet, David J. Farrell, & Ronald N. Jones. (2011). Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005–2010). Diagnostic Microbiology and Infectious Disease. 70(3). 412–416. 40 indexed citations
3.
Pfaller, Michael A., Katsura Hata, Ronald N. Jones, et al.. (2011). In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method. Diagnostic Microbiology and Infectious Disease. 71(2). 167–170. 50 indexed citations
4.
Pfaller, Michael A., Frederick P. Duncanson, S. A. Messer, et al.. (2011). In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods. Antimicrobial Agents and Chemotherapy. 55(11). 5155–5158. 64 indexed citations
5.
Pfaller, Michael A., Gary J. Moet, S. A. Messer, Ronald N. Jones, & Mariana Castanheira. (2010). Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrobial Agents and Chemotherapy. 55(2). 561–566. 191 indexed citations
6.
7.
Pfaller, Michael A., Mariana Castanheira, S. A. Messer, Gary J. Moet, & Ronald N. Jones. (2010). Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008–2009). Diagnostic Microbiology and Infectious Disease. 68(3). 278–283. 144 indexed citations
8.
Putnam, Shannon D., Hélio S. Sader, Gary J. Moet, Rodrigo E. Mendes, & Ronald N. Jones. (2010). Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagnostic Microbiology and Infectious Disease. 67(4). 359–368. 30 indexed citations
9.
Sader, Hélio S., et al.. (2010). Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 μg/mL isolated in the United States and European hospitals (2006–2008). Diagnostic Microbiology and Infectious Disease. 66(3). 329–331. 19 indexed citations
10.
Pfaller, Michael A., Mariana Castanheira, Daniel J. Diekema, et al.. (2010). Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species. Journal of Clinical Microbiology. 48(5). 1592–1599. 101 indexed citations
11.
Sader, Hélio S. & Gary J. Moet. (2009). In Vitro Activity of Ceftaroline Tested Against Recent Clinical Isolates from the United States (USA). 3 indexed citations
12.
Moet, Gary J., Amy A. Watters, Hélio S. Sader, & Ronald N. Jones. (2009). Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots. Diagnostic Microbiology and Infectious Disease. 65(3). 319–322. 16 indexed citations
13.
Putnam, Shannon D., Mariana Castanheira, Gary J. Moet, David J. Farrell, & Ronald N. Jones. (2009). CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagnostic Microbiology and Infectious Disease. 66(4). 393–401. 45 indexed citations
14.
15.
Jones, Ronald N., Thomas R. Fritsche, & Gary J. Moet. (2008). In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn®, Wyeth) formulation. Diagnostic Microbiology and Infectious Disease. 61(1). 76–79. 26 indexed citations
16.
Deshpande, Lalitagauri M., Thomas R. Fritsche, Gary J. Moet, Douglas J. Biedenbach, & Ronald N. Jones. (2007). Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagnostic Microbiology and Infectious Disease. 58(2). 163–170. 268 indexed citations
17.
Moet, Gary J., Ronald N. Jones, Douglas J. Biedenbach, Matthew G. Stilwell, & Thomas R. Fritsche. (2006). Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagnostic Microbiology and Infectious Disease. 57(1). 7–13. 315 indexed citations
18.
Moet, Gary J., Michael J. Dowzicky, & Ronald N. Jones. (2006). Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci. Diagnostic Microbiology and Infectious Disease. 57(3). 333–336. 14 indexed citations
19.
Biedenbach, Douglas J., Gary J. Moet, & Ronald N. Jones. (2004). Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002). Diagnostic Microbiology and Infectious Disease. 50(1). 59–69. 345 indexed citations
20.
Fritsche, Thomas R., Gary J. Moet, & Ronald N. Jones. (2004). Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase. Clinical Microbiology and Infection. 10(9). 857–860. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Barbara Fiori Breakdown of academic impact, for papers by Leonard B. Johnson Breakdown of academic impact, for papers by S. J. van Hal Breakdown of academic impact, for papers by D. Milatović Breakdown of academic impact, for papers by Barbara Zimmer Breakdown of academic impact, for papers by Eduardo Rodríguez-Noriega Breakdown of academic impact, for papers by Paul Lephart Breakdown of academic impact, for papers by Stacy L. Coffman Breakdown of academic impact, for papers by Josefina Ayats Breakdown of academic impact, for papers by V. Krčméry
Rankless by CCL
2026